Other substances

Hydroxychloroquine sulfate

Plasmodial heme polymerase inhibitor with anti-inflamatory properties.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Hydroxychloroquine (sulphate) has chemotherapeutic and antibacterial properties. It acts on parasites inviding erythrocytes through inhibition of plasmodial polymerase and through other unknown mechanisms. It was shown to have anti-inflamatory properties and is used for treatment of certain autoimmune diseases (NCIt).

Hydroxychloroquine might inhibit glycosylation of ACE2, which could impair SARS-CoV-2 entry into cells (DrugBank). Data of Ou et al. (2021) suggest that hydroxychloroquine blocks cathepsin L mediated viral entry in endosomes but does not impede TMPRSS2 mediated entry at the cell membrane.

On March 28, 2020, the FDA issued the Emergency Use Authorization for hydroxychloroquine sulfate for the treatment of COVID-19.

On May 23, 2020, the World Health Organization said it is temporarily halting its clinical trials that use hydroxychloroquine to treat COVID-19 patients over safety concerns. One of the key studies that lead to this conclusion was “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis", which reported the occurrence of arrhythmias associated with the use of hydroxychloroquine. This study was met with concerns regarding statistical analysis and data integrity. Following the critique, the study was retracted by three of their authors.

RECOVERY trial chief investigators stated that based on NO significant difference in 28-day mortality between hospitalized COVID-19 patients treated with hydroxychloroquine and those with usual care only, further patient recruitment was halted.

On June 15, 2020, the Emergency Use Authorization for hydroxychloroquine sulfate for the treatment of COVID-19 was REVOKED by the FDA.

On July 4, 2020, WHO announced the hydroxychloroquine arm of the Solidarity Trial in hospitalized patients was discontinued.

A living WHO guideline on drugs for covid-19 (as of March 4, 2022) strongly recommends AGAINST the use of hydroxychloroquine for the treatment of COVID-19.

Hydroxychloroquine sulfate on DrugBank
Hydroxychloroquine sulfate on PubChem
Hydroxychloroquine sulfate on Wikipedia

Marketed as

HYDROXYCHLOROQUINE SULFATE; DOLQUINE; HCQS; POLIRREUMIN; PLAQUENIL; QUENSYL

Structure image - Hydroxychloroquine sulfate

CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO.OS(=O)(=O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).	VERO E6 cell cultures		More potent than chloroquine, a dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection	Mar/09/2020
Evaluation of Flavonoids as 2019-nCoV Cell Entry Inhibitor Through Molecular Docking and Pharmacological Analysis Preprint In silico	in silico			Apr/06/2020
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial	Patients		better in combination with azithromycin	Mar/20/2020
National Consumption of Antimalarial Drugs and COVID-19 Deaths Dynamics : an Ecological Study	Patients			Apr/24/2020
Pharmacokinetic bases of the hydroxychloroquine response in COVID-19: implications for therapy and prevention	in silico		the drug needs to be administered early enough (i.e. when viral loads range from 1 to 1,000 copies/mL)	Apr/28/2020
Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring Preprint	Patients		12 % of patients treated with hydroxychloroquine plus azithromycin achieved a critical level of QTc interval prolongation	Apr/25/2020
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro	VERO E6 cell cultures		more potent than chloroquine	Mar/18/2020
A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)	Patients			Mar/06/2020
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial	Patients			Apr/10/2020
Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial Preprint Randomized controlled open trial	Patients		30 % of hydroxychloroquine recipients had adverse effects, most often diarrhea	Apr/14/2020
Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19 Preprint Critical severity	Patients			May/01/2020
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients RdRpol Small molecule Cohort study	Patients	2.16	in combination with azithromycin alone or even better in combination with azithromycin plus zinc sulfate	Sep/15/2020
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.	Patients		in combination with azithromycin	Apr/11/2020
The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators Preprint	VERO E6 cell cultures			May/21/2020
Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities Preprint Case series	Patients		in combination with doxycycline	May/22/2020
A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications. Preprint	Patients		in combination with azithromycin	Jun/12/2020
Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with hydroxychloroquine and azithromycin in Lebanon. Preprint	Patients		in combination with azithromycin	Jun/02/2020
Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 Preprint In vitro Screening	HeLa-ACE2 cells			Jun/16/2020
Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection	Patients	2.02	chronic treatment with hydroxychloroquine confers protection against SARS-CoV-2 infection	Jun/29/2020
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2 Small molecule In vitro Screening	Vero cells	5.09		Nov/25/2020
Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19 Preprint	VERO E6 cell cultures		S-enantiomer is 60% more active against SARS-CoV-2 than R-enantiomer	May/27/2020
Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo Small molecule Animal model	BALB/c mice; A549 lung adenocarcinoma cells expressing ACE2; Vero E6 cells; SARS-CoV-2 strain MA15	4.32	Inhibits the production of infectious viral particles in vitro and decreases viral gene RNA levels.	Aug/19/2020
Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study Preprint Randomized controlled open trial Moderate severity	Patients			Jun/22/2020
Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France Preprint Cohort study	Patients		higher rates of discharge home	Jun/19/2020
New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine Envelope protein Small molecule In silico	in silico	4.56	Predicted to have impact on the functionality of the SARS-CoV-2 envelope (E) protein and also to influence proofreading and capping of the viral RNA.	Aug/14/2020
A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island Small molecule Cohort study	Patients	2.71	Treatment with hydroxychloroquine/azithromycin resulted in lower ICU admission rate in patients who developed hypoxaemic pneumonia. Sample size: 23. Dosage: 400 mg twice on day 1, 200 mg twice daily on days 2-10, in combination with azithromycin (500 mg on day 1, 250 mg daily on days 2-5).	Aug/20/2020
Inhibitory activity of hydroxychloroquine on COVID-19 main protease: An insight from MD-simulation studies 3CLpro Small molecule In silico	in silico	2.46	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Jun/02/2020
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants Small molecule Cohort study	Patients	4.62	Decreased mortality irrespective of symptoms duration in patients treated with low dosage of HCQ. Sample size: 4542 + 3533 control. Dosage: 2400 mg over 5 days.	Aug/24/2020
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal Spike protein Small molecule In silico	in silico	4.62	Predicted to bind to the host's gangliosides at the virus attachment sites and thereby act synergically with azithromycin to prevent the SARS-CoV-2 infection.	May/13/2020
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate Severe severity Small molecule Case report	Patient	1.72	Used in parallel to continuous hemodiafiltration with nafamostat mesylate. Clinical improvement in a severe COVID-19 patient not responding to the lopinavir/ritonavir therapy. Dosage: 400 mg.	Aug/06/2020
Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation Small molecule In vitro	Vero E6 cells; SARS-CoV-2 IHUMI-3 strain	4.59	The antimalarial drug inhibited SARS-CoV-2 in vitro at IC50 and IC90 similar to the concentrations reached during oral antimalarial treatment.	Sep/08/2020
Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID‐19 patients Small molecule Cohort study	Patients	3.37	Administered together with azithromycin. Reduced in-hospital mortality in treated patients. Non-treated cohort patients were contraindicated for the treatment. Sample size: 297 + 63 control. Dosage: 200 mg twice daily for 10 days.	Sep/14/2020
Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus ACE2 Biophysical assay Small molecule In vitro	in silico; in vitro biophysical assay; ACE2 high-expressing HEK293T cells	4.27	Blocks SARS-CoV-2 pseudotyped virus entry into cells in vitro and binds ACE2 in vitro but is slightly more cytotoxic than chloroquine.	Sep/02/2020
Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication	Patients		Early administration of HCQ ameliorates inflamatory cytokine secretion, shortens viral shedding duration and increases viral clearance rate at 30 days. It shortens temperature recovery duration but no significant improvement in radiologic recovery duration was observred. Sample size 99. Endpoints - viral clearance rates; clinical improvement (body temperature, radiologic findings).	Jul/16/2020
Assessment of COVID‐19 Treatment containing both Hydroxychloroquine and Azithromycin: A Natural Clinical Trial Non-randomized non-controlled open trial Small molecule	Patients	2.44	In combination with azithromycin. Treatment was associated with significant reduction of COVID-19 symptoms and recovery in most patients. There was no control group within the study, however. Sample size: 161. Dosage: 400 mg twice daily on day 1; 200 mg twice daily on days 2-5 (-14 in pneumonia patients).	Nov/24/2020
Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection Protein factor Small molecule Antibody In silico	in silico (machine learning)	13.49	Considered by the authors to be among the most relevant drugs identified in a machine-learning algorithm-based screening of compounds which considers causal protein-protein interactions, known drug targets, and specific signalling circuits in	Dec/11/2020
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study Small molecule Mild severity Cohort study	Mild COVID-19 outpatients	2.69	Hydroxychloroquine use in outpatients with mild COVID-19 was associated with lower hospitalization rate compared to control. Sample size: 97 + 1177 control. Endpoint: Need for hospitalization.	Jan/14/2021
Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 Spike protein TMPRSS2 Cathepsin L In vitro Mechanism	hACE2-HEK293T cells; hACE2-H1299 cells; hACE2-H1975 cells; Vero cells; Calu-3 cells; SARS-CoV-2 S pseudovirus	6.22	Acts synergistically with	Jan/19/2021
Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism ACE2 Small molecule In silico	in silico	3.27	Predicted (especially the S enantiomer) to interact with the host's ACE2 receptor to a degree which is influenced by the polymorphisms in the receptor.	Jan/28/2021
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine... Small molecule Randomized controlled double-blind trial Moderate severity Mild severity	Mild to moderate COVID-19 patients	2.44	In combination with <a href=	Feb/09/2021

AI-suggested references

Link	Publication date
Are glucagon-like peptide 1 analogues effective and safe in severe COVID-19 patients with type 2 diabetes?-a case report.	Jan/05/2021
Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19.	Nov/10/2020
Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study.	Dec/23/2020
Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro.	Nov/22/2021
Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19	May/20/2022
Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: Molecular docking and DFT calculations.	Jan/06/2021
Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19	Aug/14/2021
Preparation and physicochemical stability of 50 mg/mL hydroxychloroquine oral suspension in SyrSpend(R) SF PH4 (dry).	Oct/16/2020
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets	Mar/24/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04389359	PROphylaxis for paTiEnts at Risk of COVID-19 infecTion	Withdrawn	Phase 2\|Phase 3	Sep/01/2020	Aug/01/2025
Alternative id - A095590 Interventions - Drug: Hydroxychloroquine Sulfate 200 MG Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to confirmed diagnosis of COVID-19\|All-cause mortality\|Severity of COVID-19 disease\|Incidence of COVID-19 complications
NCT04371926	Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk	Withdrawn	Not Applicable	Jun/01/2020	Jul/01/2021
Alternative id - TCAI_PREVENT Interventions - Drug: Hydroxychloroquine Sulfate Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Investigator)\|Primary Purpose: Prevention Enrollment - 0 Age - 18 Months to 85 Years (Child, Adult, Older Adult) Outcome measures - Time to reach normal body temperature\|Development of COVID-19 symptoms during HCQ preventive therapy in staff\|COVID-19 test result at follow-up in patients\|Worsening of symptoms in COVID-19 patients
NCT04329572	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19	Suspended	Early Phase 1	Apr/23/2020	Jun/30/2020
Alternative id - HIAPRE0320OR Interventions - Drug: Hydroxychloroquine Sulfate\|Drug: Azithromycin Tablets Study type - Interventional Study results - No Results Available Locations - Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 400 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability\|Viral load\|Change in Clinical Condition\|Evolution of Acute Respiratory Syndrome\|Hospital discharge\|Rate of mortality within 28-days
NCT04354441	Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women	Withdrawn	Phase 2	May/01/2020	May/01/2020
Alternative id - 1, March 30, 2020 Interventions - Drug: hydroxychloroquine sulfate 200 MG\|Drug: Placebo oral tablet Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years to 50 Years (Adult) Outcome measures - COVID-19-related hospital admissions\|Symptoms related to COVID-19 infection\|Adverse Events\|Maternal outcomes\|Newborn outcomes
NCT04384380	Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19	Completed	Not Applicable	Apr/01/2020	May/31/2020
Alternative id - TYGH109014 Interventions - Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil] Study type - Interventional Study results - No Results Available Locations - Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 33 Age - 20 Years to 79 Years (Adult, Older Adult) Outcome measures - Time to negatively RT-PCR\|Virologic assessment\|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
NCT04380818	Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19	Recruiting	Not Applicable	Jun/05/2020	Nov/01/2021
Alternative id - IPACOVID Interventions - Radiation: Low-dose radiotherapy\|Drug: Hydroxychloroquine Sulfate\|Drug: Ritonavir/lopinavir\|Drug: Tocilizumab Injection [Actemra]\|Drug: Azithromycin\|Drug: Corticosteroid\|Drug: Low molecular weight heparin\|Device: Oxygen supply Study type - Interventional Study results - No Results Available Locations - Hospital Sant Joan de Reus, Reus, Tarragona, Spain\|Hospital Del Mar, Barcelona, Spain\|Hospital Universitario Madrid Sanchinarro, Madrid, Spain Study designs - Allocation: Non-Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Supportive Care Enrollment - 106 Age - 18 Years to 99 Years (Adult, Older Adult) Outcome measures - Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%\|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0\|Change of the radiological image\|Overall mortality\|Measure of pro-inflammatory interleukins\|Measure of trasforming growth factor (TGF-b)\|Measure of tumor necrosis factor alpha (TNF-a)\|Determining overexpression of pro-inflammatory selectin\|Determining cell adhesion molecules (CAMs)\|Measure of marker of oxidative stress PON-1
NCT04359537	Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19	Recruiting	Phase 2	May/01/2020	Sep/25/2020
Alternative id - F.1-1/2015/ERB/SZABMU/549 Interventions - Drug: Hydroxychloroquine Sulfate 200 MG\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - Shaheed Zulfiaqar Ali Bhutto Medical University, Islamabad, Federal Capital, Pakistan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Participant)\|Primary Purpose: Prevention Enrollment - 200 Age - 18 Years to 60 Years (Adult) Outcome measures - COVID-19-free survival in experimental arms compared to placebo\|Incidence of confirmed SARS-COV-2 detection\|Incidence of possible COVID-19 symptoms\|Incidence of all-cause study medicine discontinuation\|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end\|Incidence of Hospitalization for COVID-19 or death\|Incidence of study medication-related adverse events
NCT04326725	Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia	Active, not recruiting		Mar/20/2020	Sep/01/2020
Alternative id - 2020-2/1 Interventions - Drug: Plaquenil 200Mg Tablet Study type - Observational Study results - No Results Available Locations - Istinye University Medical School, Istanbul, Turkey Study designs - Observational Model: Case-Control\|Time Perspective: Prospective Enrollment - 80 Age - 20 Years to 90 Years (Adult, Older Adult) Outcome measures - Protection against COVID-19
NCT04346667	Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds	Terminated	Phase 4	Apr/14/2020	Aug/30/2020
Alternative id - NBC-COVID19-02 Interventions - Drug: Hydroxychloroquine Sulfate Regular dose\|Drug: Hydroxychloroquine Sulfate Loading Dose\|Drug: Chloroquine\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Expo Covid Center, Lahore, Punjab, Pakistan\|Mayo Hospital, Lahore, Punjab, Pakistan\|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 125 Age - 20 Years to 50 Years (Adult) Outcome measures - RT-PCR negative status\|Progression of symptoms\|Development of Symptoms\|Adverse events
NCT04340349	Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals	Enrolling by invitation	Early Phase 1	Feb/01/2021	Jun/30/2021
Alternative id - 25/20 Interventions - Drug: Hydroxychloroquine Sulfate\|Drug: Bromhexine 8 MG Study type - Interventional Study results - No Results Available Locations - National Institute of Rehabilitation, Luis Guillermo Ibarra Ibarra, Mexico City, Cdmx, Mexico Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Prevention Enrollment - 214 Age - 18 Years to 59 Years (Adult) Outcome measures - Quantification of the expression of mRNA SARS-CoV-2 and presence or absence of antibodies anti-SARS-CoV-2
NCT04361461	Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)	Withdrawn	Phase 3	Apr/30/2020	Nov/04/2020
Alternative id - APS000/2020 Interventions - Drug: Hydroxychloroquine Sulfate\|Drug: Hydroxychloroquine Sulfate + Azythromycin Study type - Interventional Study results - No Results Available Locations - Apsen Farmacêutica S.A., São Paulo, Brazil Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Individual response rate\|All-cause mortality\|Duration of mechanical ventilation\|Proportion of patients which needed mechanical ventilation during study\|World Health Organization (WHO) Ordinal scale\|Duration of hospitalization\|Rates of drug discontinuation
NCT04446104	A Preventive Treatment for Migrant Workers at High-risk of COVID-19	Completed	Phase 3	May/13/2020	Aug/31/2020
Alternative id - 2020/00561 Interventions - Drug: Hydroxychloroquine Sulfate Tablets\|Drug: Ivermectin 3mg Tab\|Drug: Zinc\|Drug: Povidone-Iodine\|Dietary Supplement: Vitamin C Study type - Interventional Study results - No Results Available Locations - Tuas South Dormitory, Singapore, Singapore Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 4257 Age - 21 Years to 60 Years (Adult) Outcome measures - Laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)\|Acute respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)\|Febrile respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)\|Rate of hospitalization for COVID-19 and non-COVID-19 related indications in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)\|Rate of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)\|Duration of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)\|Length of hospital stay in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)\|Rate of laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)\|Adverse events and serious adverse events in control arm (Vitamin C)\|Drug discontinuation due to adverse events in control arm (Vitamin C)
NCT04342156	Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19	Withdrawn	Phase 3	Apr/01/2020	Oct/01/2020
Alternative id - 2020/00402 Interventions - Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 0 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.\|Positive serology at day 28.\|Symptoms of COVID-19.
NCT04374552	Asymptomatic COVID-19 Trial	Withdrawn	Phase 2	May/05/2020	Apr/01/2021
Alternative id - Pro2020000872 Interventions - Drug: Hydroxychloroquine sulfate &Azithromycin\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 0 Age - 20 Years and older (Adult, Older Adult) Outcome measures - The primary outcome is the rate of decline in viral load over the 10 days after randomization
NCT04354428	Treatment for COVID-19 in High-Risk Adult Outpatients	Active, not recruiting	Phase 2\|Phase 3	Apr/16/2020	Jan/01/2021
Alternative id - STUDY00009878\|INV-017062 Interventions - Drug: Ascorbic Acid\|Drug: Hydroxychloroquine Sulfate\|Drug: Azithromycin\|Drug: Folic Acid\|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] Study type - Interventional Study results - No Results Available Locations - Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States\|Tulane University, New Orleans, Louisiana, United States\|Boston University, Boston, Massachusetts, United States\|SUNY Upstate Medical University, Syracuse, New York, United States\|University of Washington Coordinating Center, Seattle, Washington, United States\|UW Virology Research Clinic, Seattle, Washington, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 300 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Lower respiratory tract infection (LRTI) rates\|Incidence of hospitalization or mortality\|Change in upper respiratory viral shedding\|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]\|Rate of participant-reported adverse events\|COVID-19-related hospitalization days\|Rate of disease severity\|Viral shedding rates\|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]
NCT04345653	Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers	Completed	Phase 2	Apr/14/2020	May/10/2021
Alternative id - Pro2020-0356 Interventions - Drug: Hydroxychloroquine Sulfate (HCQ) Study type - Interventional Study results - Has Results Locations - Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Prevention Enrollment - 48 Age - 18 Years to 99 Years (Adult, Older Adult) Outcome measures - Recruitment Feasibility\|Resource Utilization\|Safety as Reflected on the Number and Severity of Adverse Events and Serious Adverse Events\|Early Feasibility as Reflected on the Number of Participants Contracting COVID-19 (10% or Less) in Comparison to the Expected 30% as Per CDC.
NCT04348474	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19	Suspended	Early Phase 1	Apr/20/2020	Jul/31/2020
Alternative id - HIAPRE0420OR Interventions - Drug: Hydroxychloroquine Sulfate\|Drug: Azithromycin Tablets Study type - Interventional Study results - No Results Available Locations - Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 200 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Change in Clinical Condition\|Hospitalization\|Rate of mortality within 28-days\|Change in Clinical Condition related to comorbidity
NCT04329923	The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)	Terminated	Phase 2	Apr/09/2020	Nov/13/2020
Alternative id - 842838 Interventions - Drug: Hydroxychloroquine Sulfate 400 mg twice a day\|Drug: Hydroxychloroquine Sulfate 600 mg twice a day\|Drug: Hydroxychloroquine Sulfate 600 mg once a day\|Drug: Placebo oral tablet Study type - Interventional Study results - Has Results Locations - University of Pennsylvania, Philadelphia, Pennsylvania, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Participant, Care Provider, Investigator)\|Primary Purpose: Treatment Enrollment - 173 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Time to Release From Quarantine Time\|Time to Hospital Discharge\|Number of Health Care Workers Who Developed SARS-COV-2 Infection\|Rate of Housemate Infection\|Rate of Hospitalization
NCT04336332	Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19	Active, not recruiting	Phase 2	Apr/01/2020	Jun/30/2022
Alternative id - Pro2020000712\|002011 Interventions - Combination Product: Hydroxychloroquine Sulfate + Azithromycin\|Drug: Hydroxychloroquine Sulfate Study type - Interventional Study results - No Results Available Locations - Saint Barnabas Medical Center, Livingston, New Jersey, United States\|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States\|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States\|The University Hospital, Newark, New Jersey, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 160 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Changes in patients viral load\|Second evaluation of changes in patients viral load\|Symptom questionnaire\|Fever assessment\|Vital Signs - Body Temperature\|Discharge\|Recovery\|Assessment of agent toxicity\|Oropharynx swab sample collections\|Blood Sample collections\|Viral shedding assessment - nasopharyngeal secretions\|Viral shedding assessment - serology\|Cytokines in blood
NCT04341727	Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection	Terminated	Phase 3	Apr/04/2020	Apr/01/2021
Alternative id - 202003188 Interventions - Drug: Hydroxychloroquine Sulfate\|Drug: Azithromycin\|Drug: Chloroquine Sulfate Study type - Interventional Study results - No Results Available Locations - Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States\|Washington University School of Medicine, Saint Louis, Missouri, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 31 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Hours to recovery\|Time fever resolution
NCT04342221	Hydroxychloroquine for COVID-19	Terminated	Phase 3	Mar/29/2020	Feb/26/2021
Alternative id - COV-HCQ\|2020-001224-33 Interventions - Drug: Hydroxychloroquine Sulfate\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Zollernalb Klinikum Balingen, Balingen, Germany\|Klinikum Darmstadt, Darmstadt, Germany\|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany\|Johannes Wesling Klinikum Minden, Minden, Germany\|Klinikum am Steinenberg, Reutlingen, Germany\|RoMed Klinikum Rosenheim, Rosenheim, Germany\|Robert-Bosch-Krankenhaus, Stuttgart, Germany\|Institute for Tropical Medicine, Tübingen, Germany Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 30 Age - 18 Years to 99 Years (Adult, Older Adult) Outcome measures - Effect of HCQ on in vivo viral clearance
NCT04307693	Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)	Terminated	Phase 2	Mar/11/2020	Apr/30/2020
Alternative id - S2020-0472-0001 Interventions - Drug: Lopinavir/ritonavir\|Drug: Hydroxychloroquine sulfate Study type - Interventional Study results - No Results Available Locations - Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 65 Age - 16 Years to 99 Years (Child, Adult, Older Adult) Outcome measures - Viral load\|Viral load change\|Time to clinical improvement (TTCI)\|Percentage of progression to supplemental oxygen requirement by day 7\|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7\|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission\|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7\|adverse effects\|Concentration of Lopinavir/ritonavir and hydroxychloroquine
NCT04403100	Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"	Recruiting	Phase 3	Jun/03/2020	Feb/01/2021
Alternative id - COVID19_AMB_Brasil Interventions - Drug: Hydroxychloroquine Sulfate Tablets\|Drug: Lopinavir/ Ritonavir Oral Tablet\|Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil\|Pontificia Universidade Catolica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil\|Fundo Municipal de Saúde de Betim, Betim, Minas Gerais, Brazil\|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil Study designs - Allocation: Randomized\|Intervention Model: Factorial Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 1968 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Proportion of participants who were hospitalized for progression of COVID-19 disease\|Proportion of participants who died due to COVID-19 progression and/ or complications\|Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization\|Time to clinical improvement\|Time to clinical failure\|Hospitalization for any cause\|Proportion of participants who died due to pulmonary complications\|Proportion of participants who died due to cardiovascular complications\|Proportion of participants who presented with adverse events\|Time to improvement on respiratory scale symptoms\|proportion of non-adherent participants to any of study drugs
NCT04392128	Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)	Withdrawn	Phase 2	Sep/02/2020	Sep/02/2020
Alternative id - 2020-005\|2020-002002-45 Interventions - Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]\|Drug: Azithromycin 250 MG Oral Capsule\|Drug: Placebo oral tablet\|Drug: Placebo oral capsule Study type - Interventional Study results - No Results Available Locations - Institut de Cancérologie Strasbourg Europe, Strasbourg, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 0 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.\|Clinical evolution\|Proportion of patients progressing to a severe form\|Mortality\|Evaluation of viral load drop\|Tolerance of study treatment\|Evaluation of the seroconversion\|NK immunological study\|Hospitalisation duration\|Impact of the study treatment on the treatment of the hematological disease\|Monitoring of the QT space\|Dosage of residual concentration of azithromycine and hydroxychloroquine.\|T immunological study
NCT04351191	PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds	Terminated	Phase 4	Apr/15/2020	Aug/30/2020
Alternative id - NBC-COVID1902 Interventions - Drug: Hydroxychloroquine Sulfate Regular dose\|Drug: Hydroxychloroquine Sulfate Loading Dose\|Drug: Chloroquine\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan\|Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan\|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan\|Services Hospital, Lahore, Punjab, Pakistan Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 137 Age - 20 Years to 50 Years (Adult) Outcome measures - RT-PCR result\|Progression of symptoms\|Mortality
NCT04316377	Norwegian Coronavirus Disease 2019 Study	Active, not recruiting	Phase 4	Mar/25/2020	Mar/03/2025
Alternative id - REC 121446 Interventions - Drug: Hydroxychloroquine Sulfate Study type - Interventional Study results - No Results Available Locations - Akershus University Hospital, Lørenskog, Norway Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 53 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Rate of decline in SARS-CoV-2 viral load\|Change in National Early Warning Score score\|Admission to intensive care unit\|In-hospital mortality\|Duration of hospital admission\|Mortality at 30 and 90 days\|Clinical status\|Change in C-reactive protein concentrations\|Change in alanine aminotransferase concentrations\|Change in aspartate aminotransferase concentrations\|Change in bilirubin concentrations\|Change in estimated glomerular filtration rate\|Change in cardiac troponin concentrations\|Change in natriuretic peptide concentrations
NCT04328961	Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)	Completed	Phase 2\|Phase 3	Mar/31/2020	Oct/08/2020
Alternative id - STUDY00009750\|INV-016204 Interventions - Drug: Hydroxychloroquine Sulfate\|Drug: Ascorbic Acid Study type - Interventional Study results - Has Results Locations - University of California Los Angeles, Los Angeles, California, United States\|Tulane, New Orleans, Louisiana, United States\|University of Maryland, Baltimore, Baltimore, Maryland, United States\|Boston University, Boston, Massachusetts, United States\|NYU Langone Health, New York, New York, United States\|SUNY Upstate Medical University, Syracuse, New York, United States\|University of Washington, Coordinating Center, Seattle, Washington, United States\|UW Virology Research Clinic, Seattle, Washington, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Prevention Enrollment - 943 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection\|The Number of Participants Who Had Polymerase Chain Reaction (PCR) Confirmed SARS-CoV-2 Infection\|Rate of Participant-reported Adverse Events\|Number of Participants Who Had COVID-19 Disease
NCT04461353	A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers	Completed	Phase 1	Jun/25/2020	Aug/17/2020
Alternative id - PUL-01 Interventions - Drug: Aerolized Hydroxychloroquine Sulfate\|Other: Placebo Study type - Interventional Study results - No Results Available Locations - The Rockefeller University, New York, New York, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 12 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Incidences of treatment-emergent adverse events (TEAEs) as assessed by TGSHAAV (September 2007) or CTCAE version 5.0\|Change from baseline in clinical laboratory test results for CBC with differential\|Incidence of abnormal laboratory test results for CBC with differential at Screening\|Incidence of abnormal laboratory test results for CBC with differential - Day 8\|Changes from baseline for blood glucose\|Incidence of abnormal laboratory test results for chemistry -Screening\|Incidence of abnormal laboratory tests results for chemistry - Day 8\|Incidence of abnormal laboratory tests results for urinalysis - Screening\|Incidence of abnormal laboratory tests results for urinalysis- Day 8\|Changes in vital signs from baseline (pre-dose) - respiratory rate\|Changes in vital signs from baseline (pre-dose)- temperature\|Changes in vital signs from baseline (pre-dose) - seated blood pressure\|Changes in vital signs from baseline (pre-dose) - pulse\|Changes in vital signs from baseline (pre-dose) - O2 saturation\|Incidence of abnormal and physical examinations findings during Screening- general appearance\|Incidence of abnormal and physical examinations findings on Day 1 - general appearance\|Incidence of abnormal and physical examinations findings on Day 2- general appearance\|Incidence of abnormal and physical examinations findings on Day 8- general appearance\|Incidence of abnormal and physical examinations findings during Screening- neurological\|Incidence of abnormal and physical examinations findings on Day 1- neurological\|Incidence of abnormal and physical examinations findings on Day 2- neurological\|Incidence of abnormal and physical examinations findings on Day 8- neurological\|Incidence of abnormal and physical examinations findings during Screening - heart/cardiovascular\|Incidence of abnormal and physical examinations findings on Day 1 - heart/cardiovascular\|Incidence of abnormal and physical examinations findings on Day 2 - heart/cardiovascular\|Incidence of abnormal and physical examinations findings on Day 8 - heart/cardiovascular\|Incidence of abnormal and physical examinations findings during Screening - lungs\|Incidence of abnormal and physical examinations findings on Day 1 - lungs\|Incidence of abnormal and physical examinations findings on Day 2 - lungs\|Incidence of abnormal and physical examinations findings on Day 8 - lungs\|Incidence of abnormal and physical examinations findings during Screening- abdomen\|Incidence of abnormal and physical examinations findings on Day 1 - abdomen\|Incidence of abnormal and physical examinations findings on Day 2- abdomen\|Incidence of abnormal and physical examinations findings on Day 8- abdomen\|Incidence of abnormal and physical examinations findings during screening- endocrine\|Incidence of abnormal and physical examinations findings on Day 1 - endocrine\|Incidence of abnormal and physical examinations findings on Day 2- endocrine\|Incidence of abnormal and physical examinations findings on Day 8- endocrine\|Incidence of abnormal and physical examinations findings during Screening- extremities\|Incidence of abnormal and physical examinations findings on Day 1- extremities\|Incidence of abnormal and physical examinations findings on Day 2- extremities\|Incidence of abnormal and physical examinations findings on Day 8- extremities\|Incidence of abnormal and physical examinations findings during Screening- lymphatic\|Incidence of abnormal and physical examinations findings on Day 1- lymphatic\|Incidence of abnormal and physical examinations findings on Day 2 - lymphatic\|Incidence of abnormal and physical examinations findings on Day 8- lymphatic\|Incidence of abnormal and physical examinations findings during screening - skin\|Incidence of abnormal and physical examinations findings on Day 1 - skin\|Incidence of abnormal and physical examinations findings on Day 2 - skin\|Incidence of abnormal and physical examinations findings on Day 8 - skin\|Changes from baseline for pulmonary function tests (PFTs) - FEV1\|Changes from baseline for pulmonary function tests (PFTs) - FVC\|Changes from baseline for pulmonary function tests (PFTs) - FEV1/FVC\|Changes from baseline for ECG readings - QT interval\|Changes from baseline for ECG readings - QTcB Interval\|Changes from baseline for ECG readings - QRS duration\|Changes from baseline for ECG readings - PR interval\|Changes from baseline for ECG readings - heart rate\|Incidence of abnormal ECG - Screening\|Incidence of abnormal ECG- Day 1\|Incidence of abnormal ECG - Day 2\|Incidence of abnormal ECG - Day 8\|HCQ concentration in whole blood versus time profiles

Export (.csv)